Literature DB >> 24006943

Melatonin ameliorates vascular endothelial dysfunction, inflammation, and atherosclerosis by suppressing the TLR4/NF-κB system in high-fat-fed rabbits.

Ze-Ping Hu1, Xiao-Ling Fang, Nan Fang, Xiao-Bian Wang, Hai-Yan Qian, Zhong Cao, Yuan Cheng, Bang-Ning Wang, Yuan Wang.   

Abstract

Vascular endothelial dysfunction (VED) and inflammation contribute to the initiation and progression of atherosclerosis. Melatonin (MLT) normalizes lipid profile, improves endothelial function, and possesses anti-inflammatory properties. However, the precise mechanisms are still unclear. This study investigated whether MLT could ameliorate VED, inflammation, and atherosclerosis by suppressing the Toll-like receptor 4 (TLR4)/nuclear factor kappa B (NF-κB) system in high-fat-fed rabbits. Rabbits were randomly divided into three groups that received a standard diet (control group), high-cholesterol diet (atherosclerosis group), or high-cholesterol diet plus 10 mg/kg/day MLT (MLT group) for 12 wk. After treatment, high-fat diet significantly increased serum lipid and inflammatory markers in rabbits in atherosclerosis group compared with that in control group. In addition, high-fat diet also induced VED and typical atherosclerotic plaque formation and increased intima/media thickness ratio, which were significantly improved by MLT therapy as demonstrated in MLT group. Histological and immunoblot analysis further showed that high-fat diet enhanced the expressions of TLR4, myeloid differentiation primary response protein (MyD88), and NF-κB p65, but decreased inhibitor of NF-κB (IκB) expression. By contrast, MLT therapy decreased the expressions of TLR4, MyD88, and NF-κB p65 and increased IκB expression. This study has demonstrated that MLT ameliorates lipid metabolism, VED, and inflammation and inhibits the progression of atherosclerosis in high-fat-fed rabbits. Moreover, our study indicates for the first time that suppression of the TLR4/NF-κB system in local vasculature with atherosclerotic damage is important for the protective effects of MLT.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  TLR4/NF-κB system; atherosclerosis; inflammation; melatonin; vascular endothelial function

Mesh:

Substances:

Year:  2013        PMID: 24006943     DOI: 10.1111/jpi.12085

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  27 in total

Review 1.  Effects of melatonin on cardiovascular risk factors and metabolic syndrome: a comprehensive review.

Authors:  Mohsen Imenshahidi; Golamreza Karimi; Hossein Hosseinzadeh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-01-30       Impact factor: 3.000

2.  Melatonin, the Hormone of Darkness: From Sleep Promotion to Ebola Treatment.

Authors:  Alina Masters; Seithikurippu R Pandi-Perumal; Azizi Seixas; Jean-Louis Girardin; Samy I McFarlane
Journal:  Brain Disord Ther       Date:  2014

Review 3.  Melatonin as an anti-inflammatory agent in radiotherapy.

Authors:  M Najafi; A Shirazi; E Motevaseli; A H Rezaeyan; A Salajegheh; S Rezapoor
Journal:  Inflammopharmacology       Date:  2017-03-02       Impact factor: 4.473

Review 4.  Snapshot: implications for melatonin in endoplasmic reticulum homeostasis.

Authors:  Wei Hu; Zhiqiang Ma; Shouyin Di; Shuai Jiang; Yue Li; Chongxi Fan; Yang Yang; Dongjin Wang
Journal:  Br J Pharmacol       Date:  2016-11-16       Impact factor: 8.739

5.  TLR4/NF-κB signaling contributes to chronic unpredictable mild stress-induced atherosclerosis in ApoE-/- mice.

Authors:  Ya Ling Tang; Jian Hong Jiang; Shuang Wang; Zhu Liu; Xiao Qing Tang; Juan Peng; Yong-Zong Yang; Hong-Feng Gu
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

6.  TLR4-mediated inflammation promotes foam cell formation of vascular smooth muscle cell by upregulating ACAT1 expression.

Authors:  Y W Yin; S Q Liao; M J Zhang; Y Liu; B H Li; Y Zhou; L Chen; C Y Gao; J C Li; L L Zhang
Journal:  Cell Death Dis       Date:  2014-12-18       Impact factor: 8.469

7.  Myosin light chain kinase inhibitor ML7 improves vascular endothelial dysfunction via tight junction regulation in a rabbit model of atherosclerosis.

Authors:  Xiaowen Cheng; Xiaobian Wang; Yufeng Wan; Qing Zhou; Huaqing Zhu; Yuan Wang
Journal:  Mol Med Rep       Date:  2015-06-22       Impact factor: 2.952

8.  Orally administered melatonin prevents lipopolysaccharide-induced neural tube defects in mice.

Authors:  Lin Fu; Zhen Yu; Yuan-Hua Chen; Mi-Zhen Xia; Hua Wang; Cheng Zhang; Fang-Biao Tao; De-Xiang Xu
Journal:  PLoS One       Date:  2014-11-24       Impact factor: 3.240

9.  Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer.

Authors:  Luiz Gustavo A Chuffa; Beatriz A Fioruci-Fontanelli; Leonardo O Mendes; Fábio R Ferreira Seiva; Marcelo Martinez; Wagner J Fávaro; Raquel F Domeniconi; Patrícia F F Pinheiro; Lucilene Delazari Dos Santos; Francisco Eduardo Martinez
Journal:  BMC Cancer       Date:  2015-02-06       Impact factor: 4.430

Review 10.  Clinical Application of Melatonin in the Treatment of Cardiovascular Diseases: Current Evidence and New Insights into the Cardioprotective and Cardiotherapeutic Properties.

Authors:  Mohammad Hossein Pourhanifeh; Ehsan Dehdashtian; Azam Hosseinzadeh; Seyed Hashem Sezavar; Saeed Mehrzadi
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-14       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.